Answers are grounded in this paper and cite their sources.
receptor inverse agonist/antagonist being evaluated clinically for its potential to treat Alzheimer disease psychosis and Lewy body dementia psychosis. Comprehensive nonclinical evaluations shown herein demonstrate that ACP-204 has optimized pharmacodynamic properties resulting in a favorable safety/tolerability profile, a broad therapeutic index, and promising effectiveness.
No takes yet. Share an insight, caveat, or question.
Burstein et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: